AR089445A1 - Heteroarilos y sus usos - Google Patents

Heteroarilos y sus usos

Info

Publication number
AR089445A1
AR089445A1 ARP120104956A ARP120104956A AR089445A1 AR 089445 A1 AR089445 A1 AR 089445A1 AR P120104956 A ARP120104956 A AR P120104956A AR P120104956 A ARP120104956 A AR P120104956A AR 089445 A1 AR089445 A1 AR 089445A1
Authority
AR
Argentina
Prior art keywords
optionally substituted
nitrogen
membered
sulfur
oxygen
Prior art date
Application number
ARP120104956A
Other languages
English (en)
Inventor
W Chau Ryan
J Vos Tricia
E Gipson Krista
Hu Yongbo
A Cullis Courtney
O Duffey Matthew
Li Gang
D Sintchak Michael
Original Assignee
Millennium Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Millennium Pharm Inc filed Critical Millennium Pharm Inc
Publication of AR089445A1 publication Critical patent/AR089445A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/36—Oxygen or sulfur atoms
    • C07D207/40—2,5-Pyrrolidine-diones
    • C07D207/416—2,5-Pyrrolidine-diones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems

Abstract

Reivindicación 1: Un compuesto de fórmula (1) o una sal del mismo farmacéuticamente aceptable, caracterizado porque: -G⁵-G⁶-G⁷-G⁸-G⁹ es -CR³=C-N-N=C, -CR³=C-N-CR³=C, =CR³-C=C-NR¹⁵-C, =CR³-N-C=CR³-C, =N-N-C=CR³-C o -NR¹⁵-C=C-CR³=C; cuando G⁵ y G⁶ ambos son nitrógeno, o G⁷ y G⁸ ambos son nitrógeno, entonces R³ es hidrógeno, -CN, halógeno, -Z-R⁵, o un grupo opcionalmente sustituido seleccionado de alifático C₁₋₆ y cicloalifático 3 a 10-miembros, en donde: Z es seleccionado de una cadena alquileno C₁₋₃ opcionalmente sustituida, -O-, -N(R³ᵃ)-, -S-, -S(O)-, -S(O)₂-, -C(O)-, -CO₂-, -C(O)NR³ᵃ-, -N(R³ᵃ)C(O)-, -N(R³ᵃ)CO₂-, -S(O)₂NR³ᵃ-, -N(R³ᵃ)S(O)₂, -OC(O)N(R³ᵃ)-, -N(R³ᵃ)C(O)NR³ᵃ-, -N(R³ᵃ)S(O)₂N(R³ᵃ)-, o -OC(O)-; R³ᵃ es hidrógeno o un alifático C₁₋₄ opcionalmente sustituido, y R⁵ es hidrógeno o un grupo opcionalmente sustituido seleccionado de alifático C₁₋₆, cicloalifático 3 a 10-miembros, heterociclilo 4 a 10-miembros que tiene 1 - 5 heteroátomos independientemente seleccionados de nitrógeno, oxígeno, o azufre, arilo 6 a 10-miembros o heteroarilo 5 a 10-miembros que tiene 1 - 5 heteroátomos independientemente seleccionados de nitrógeno, oxígeno, o azufre; cuyo G⁵ es CR³ y G⁶ es nitrógeno, o G⁶ es carbono y G⁵ es NR¹⁵, o G⁷ es N y G⁸ es CR³, o G⁷ es C y G⁸ es NR¹⁵ entonces cada aparición de R³ es independientemente hidrógeno, CN, o un alifático C₁₋₃ opcionalmente sustituido; R¹⁵ es hidrógeno, ciclopropilo, o un grupo alifático C₁₋₆ opcionalmente sustituido; R¹ es -CN, -C(O)N(R⁴)₂, -C(O)OR⁴, -C(NR⁴)N(R⁴)₂, -NHCOR⁴, -NHSO₂R⁴, -NHCON(R⁴)₂, -NHCOOR⁴, -NHSO₂N(R⁴)₂, -CH₂OR⁴, -CH₂N(R⁴)₂, -CH₂NHC(O)R⁴, -SO₂N(R⁴)₂, -C(O)NHC(=NH)N(R⁴)₂, -NHSO₂OR⁴, o CY, en donde CY es un grupo opcionalmente sustituido seleccionado de un cicloalifático de 3 a 7 miembros; un heterociclilo de 4 a 10 miembros que tiene 1 - 5 heteroátomos independientemente seleccionados de nitrógeno, oxígeno, o azufre; un arilo 6 a 10-miembros, o heteroarilo 5 a 10-miembros que tiene 1 - 5 heteroátomos independientemente seleccionados de nitrógeno, oxígeno, o azufre; en donde cada R⁴ es independientemente seleccionado de hidrógeno, -OH, o un grupo opcionalmente sustituido seleccionado de alifático C₁₋₆, cicloalifático 3 a 10-miembros, arilo 6 a 10-miembros, o heteroarilo 5 a 10-miembros que tiene 1 - 5 heteroátomos independientemente seleccionados de nitrógeno, oxígeno, o azufre; o R⁴ es -Z²-R⁶ en donde: Z² es seleccionado de una cadena alquileno C₁₋₃ opcionalmente sustituida, -S(O)-, -S(O)₂-, -C(O)-, -CO₂-, -C(O)NR⁴ᵃ-, -C(NH)-, o -S(O)₂NR⁴ᵃ-; R⁴ᵃ es hidrógeno o un alifático C₁₋₄ opcionalmente sustituido, y R⁶ es hidrógeno, -NH₂, o un grupo opcionalmente sustituido seleccionado de alifático C₁₋₆, cicloalifático 3 a 10-miembros, heterociclilo 4 a 10-miembros que tiene 1 - 5 heteroátomos independientemente seleccionados de nitrógeno, oxígeno, o azufre, arilo 6 a 10-miembros, o heteroarilo 5 a 10-miembros que tiene 1 - 5 heteroátomos independientemente seleccionados de nitrógeno, oxígeno, o azufre; o dos apariciones de R⁴, tomados juntos con un átomo de nitrógeno al cual están unidos, forman un anillo heterociclilo de 4 a 7 miembros opcionalmente sustituido que tiene 0 - 1 heteroátomos adicionales independientemente seleccionados de nitrógeno, oxígeno, o azufre; R² es hidrógeno, halo, o un grupo opcionalmente sustituido seleccionado de alifático C₁₋₆, cicloalifático 3 a 10-miembros, heterociclilo 4 a 10-miembros que tiene 1 - 5 heteroátomos independientemente seleccionados de nitrógeno, oxígeno, o azufre, arilo 6 a 10-miembros, o heteroarilo 5 a 10-miembros que tiene 1 - 5 heteroátomos independientemente seleccionados de nitrógeno, oxígeno, o azufre, en donde R² es opcionalmente sustituido con 1 - 4 apariciones de R²ᵃ, en donde cada aparición de R²ᵃ es independientemente -R¹²ᵃ, -T²-R¹²ᵈ, -T²-R¹²ᵃ, o -V²-T²-R¹²ᵈ, y: cada aparición de R¹²ᵃ es independientemente halógeno, -CN, -NO₂, -R¹²ᶜ, -N(R¹²ᵇ)₂, -OR¹²ᵇ, -SR¹²ᶜ, -S(O)₂R¹²ᶜ, -C(O)R¹²ᵇ, -C(O)OR¹²ᵇ, -C(O)N(R¹²ᵇ)₂, -S(O)₂N(R¹²ᵇ)₂, -OC(O)N(R¹²ᵇ)₂, -N(R¹²ᵉ)C(O)R¹²ᵇ, -N(R¹²ᵉ)SO₂R¹²ᶜ, -N(R¹²ᵉ)C(O)OR¹²ᵇ, -N(R¹²ᵉ)C(O)N(R¹²ᵇ)₂, o -N(R¹²ᵉ)SO₂N(R¹²ᵇ)₂, o un alifático C₁₋₆ o haloalifático C₁₋₆ opcionalmente sustituido; cada aparición de R¹²ᵇ es independientemente hidrógeno o un grupo opcionalmente sustituido seleccionado de alifático C₁₋₆, cicloalifático 3 a 10-miembros, heterociclilo 4 a 10-miembros que tiene 1 - 5 heteroátomos independientemente seleccionados de nitrógeno, oxígeno, o azufre, arilo 6 a 10-miembros o heteroarilo 5 a 10-miembros que tiene 1 - 5 heteroátomos independientemente seleccionados de nitrógeno, oxígeno, o azufre, o dos apariciones de R¹²ᵇ, tomados juntos con un átomo de nitrógeno al cual están unidos, forman un anillo heterociclilo de 4 a 7 miembros opcionalmente sustituido que tiene 0 - 1 heteroátomos adicionales seleccionado de nitrógeno, oxígeno, o azufre; cada aparición de R¹²ᶜ es independientemente hidrógeno o un grupo opcionalmente sustituido seleccionado de alifático C₁₋₆, haloalifático C₁₋₆, cicloalifático 3 a 10-miembros, heterociclilo 4 a 10-miembros que tiene 1 - 5 heteroátomos independientemente seleccionados de nitrógeno, oxígeno, o azufre, arilo 6 a 10-miembros, o heteroarilo 5 a 10-miembros que tiene 1 - 5 heteroátomos independientemente seleccionados de nitrógeno, oxígeno, o azufre; cada aparición de R¹²ᵈ es independientemente hidrógeno o un grupo opcionalmente sustituido seleccionado de cicloalifático 3 a 10-miembros, heterociclilo 4 a 10-miembros que tiene 1 - 5 heteroátomos independientemente seleccionados de nitrógeno, oxígeno, o azufre, arilo 6 a 10-miembros o heteroarilo 5 a 10-miembros que tiene 1 - 5 heteroátomos independientemente seleccionados de nitrógeno, oxígeno, o azufre; cada aparición de R¹²ᵉ es independientemente hidrógeno o un grupo alifático C₁₋₆ opcionalmente sustituido; cada aparición de V² es independientemente -N(R¹²ᵉ)-, -O-, -S-, -S(O)-, -S(O)₂-, -C(O)-, -C(O)O-, -C(O)N(R¹²ᵉ)-, -S(O)₂N(R¹²ᵉ)-, -OC(O)N(R¹²ᵉ)-, -N(R¹²ᵉ)C(O)-, -N(R¹²ᵉ)SO₂-, -N(R¹²ᵉ)C(O)O-, -N(R¹²ᵉ)C(O)N(R¹²ᵉ)-, -N(R¹²ᵉ)SO₂N(R¹²ᵉ)-, -OC(O)-, o -C(O)N(R¹²ᵉ)-O-; y T² es una cadena alquileno C₁₋₆ opcionalmente sustituido en donde la cadena alquileno es opcionalmente interrumpida por -N(R¹³)-, -O-, -S-, -S(O)-, -S(O)₂-, -C(O)-, -C(O)O-, -C(O)N(R¹³)-, -S(O)₂N(R¹³)-, -OC(O)N(R¹³)-, -N(R¹³)C(O)-, -N(R¹³)SO₂-, -N(R¹³)C(O)O-, -N(R¹³)C(O)N(R¹³)-, -N(R¹³)S(O)₂N(R¹³)-, -OC(O)-, o -C(O)N(R¹³)-O- o en donde T² o una porción del mismo opcionalmente forma parte de un cicloalifático de 3 a 7 miembros opcionalmente sustituido o anillo heterociclilo en donde R¹³ es hidrógeno o un grupo alifático C₁₋₄ opcionalmente sustituido; y HY es un compuesto seleccionado del grupo de fórmulas (2) en donde cada aparición de X⁴, X⁵, X⁶, X⁷, y X⁸ es independientemente -CR¹⁰, -CR¹⁰, o N, siempre que no más de dos apariciones de X⁴, X⁵, X⁶, X⁷, y X⁸ es N; cada aparición de Y¹, Y², Y³, Y⁴, Y⁵, Y⁶, Y⁷, y Y⁸ es -CR¹⁰; cada aparición de Q¹ y Q² es independientemente S, O ó -NR⁹; dos apariciones adyacentes de X⁴ y X⁵, X⁶ y X⁷, X⁷ y X⁸, Y¹ y -NR⁹, Y³ y -NR⁹, o Y⁴ y Y⁵, pueden ser tomados juntos con los átomos al cual están unidos, para formar un grupo heteroarilo o heterociclilo fusionado no sustituido que tiene de 8 a 10 átomos y que tiene 1 - 5 heteroátomos independientemente seleccionados de nitrógeno, oxígeno, o azufre; cada aparición de R¹⁰ o R¹⁰ es independientemente -R¹⁰ᵇ, -V¹-R¹⁰ᶜ, -T¹-R¹⁰ᵇ, o -V¹-T¹-R¹⁰ᵇ, en donde V¹ es -NR¹¹-, -NR¹¹-C(O)-, -NR¹¹-C(S)-, -NR¹¹C(NR¹¹)-, -NR¹¹C(O)O-, -NR¹¹C(O)NR¹¹-, -NR¹¹C(O)S-, -NR¹¹C(S)O-, -NR¹¹(S)NR¹¹-, -NR¹¹C(S)S-, -NR¹¹C(NR¹¹)O-, -NR¹¹C(NR¹¹)NR¹¹-, -NR¹¹S(O)₂-, -NR¹¹S(O)₂NR¹¹-, -C(O)-, -CO₂-, -C(O)NR¹¹-, -C(O)NR¹¹O-, -SO₂-, o -SO₂NR¹¹-; cada aparición de R¹⁰ᵃ es independientemente hidrógeno o un grupo opcionalmente sustituido seleccionado de alifático C₁₋₆, cicloalifático 3 a 10-miembros, heterociclilo 4 a 10-miembros que tiene 1 - 5 heteroátomos independientemente seleccionados de nitrógeno oxígeno, o azufre, arilo 6 a 10-miembros o heteroarilo 5 a 10-miembros que tiene 1 - 5 heteroátomos independientemente seleccionados de nitrógeno, oxígeno, o azufre; T¹ es una cadena alquileno C₁₋₆ opcionalmente sustituida en donde la cadena a
ARP120104956A 2011-12-23 2012-12-26 Heteroarilos y sus usos AR089445A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161579711P 2011-12-23 2011-12-23
US201261672030P 2012-07-16 2012-07-16
US201261716172P 2012-10-19 2012-10-19

Publications (1)

Publication Number Publication Date
AR089445A1 true AR089445A1 (es) 2014-08-27

Family

ID=48655164

Family Applications (3)

Application Number Title Priority Date Filing Date
ARP120104957A AR089446A1 (es) 2011-12-23 2012-12-26 Heteroarilos y usos de los mismos
ARP120104958A AR089447A1 (es) 2011-12-23 2012-12-26 Heteroarilos nitrogenados y sus usos
ARP120104956A AR089445A1 (es) 2011-12-23 2012-12-26 Heteroarilos y sus usos

Family Applications Before (2)

Application Number Title Priority Date Filing Date
ARP120104957A AR089446A1 (es) 2011-12-23 2012-12-26 Heteroarilos y usos de los mismos
ARP120104958A AR089447A1 (es) 2011-12-23 2012-12-26 Heteroarilos nitrogenados y sus usos

Country Status (7)

Country Link
US (3) US20130165483A1 (es)
EP (3) EP2793880A4 (es)
JP (3) JP2015503504A (es)
AR (3) AR089446A1 (es)
TW (3) TW201332989A (es)
UY (3) UY34538A (es)
WO (3) WO2013096637A1 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2250160B1 (en) 2008-01-25 2015-11-11 Millennium Pharmaceuticals, Inc. Thiophenes and their use as phosphatidylinositol 3-kinase (pi3k) inhibitors
US8796314B2 (en) 2009-01-30 2014-08-05 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
CA2750935A1 (en) 2009-01-30 2010-08-12 Millennium Pharmaceuticals, Inc. Heteroaryls and their use as pi3k inhibitors
US9090601B2 (en) 2009-01-30 2015-07-28 Millennium Pharmaceuticals, Inc. Thiazole derivatives
EP2603216A4 (en) 2010-08-11 2013-12-18 Millennium Pharm Inc HETEROARYLE AND USES THEREOF
MA34797B1 (fr) 2010-08-11 2014-01-02 Millennium Pharm Inc Hétéroaryles et leurs utilisations
US9062038B2 (en) 2010-08-11 2015-06-23 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
EP2627181A4 (en) 2010-10-13 2014-03-19 Millennium Pharm Inc HETEROARYLE AND USES THEREOF
ES2676585T3 (es) 2013-08-28 2018-07-23 Medivation Technologies Llc Compuestos heterocíclicos y métodos de uso
GEP20196983B (en) 2014-01-14 2019-06-25 Millennium Pharm Inc Heteroaryls and uses thereof
US10202373B2 (en) 2014-01-14 2019-02-12 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
JP6507234B2 (ja) * 2014-10-02 2019-04-24 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ブルトンチロシンキナーゼ（ｂｔｋ）によって介入される障害の処置における使用のためのピラゾールカルボキサミド化合物
WO2016141258A1 (en) 2015-03-04 2016-09-09 Medivation Technologies, Inc. Sterol regulatory element-binding proteins (srebps) inhibitors
EP3265088A1 (en) 2015-03-04 2018-01-10 Medivation Technologies LLC Srebp blockers for use in treating liver fibrosis, elevated cholesterol and insulin resistance
US20190053492A1 (en) 2016-03-16 2019-02-21 Bayer Cropscience Aktiengesellschaft Substituted pyridine compounds as pesticides
EP3284739A1 (de) 2017-07-19 2018-02-21 Bayer CropScience Aktiengesellschaft Substituierte (het)arylverbindungen als schädlingsbekämpfungsmittel
UA125317C2 (uk) 2017-07-28 2022-02-16 Юхан Корпорейшн Удосконалений спосіб отримання похідних амінопіримідину
BR112020001457A2 (pt) 2017-07-28 2020-07-28 Yuhan Corporation intermediários úteis para a síntese de um inibidor seletivo contra proteína quinase e processos para preparar os mesmos
US11034669B2 (en) 2018-11-30 2021-06-15 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
CN110041252A (zh) * 2019-05-22 2019-07-23 南京合巨药业有限公司 一种2-氯-4-肼基吡啶的制备方法
WO2021011720A2 (en) * 2019-07-18 2021-01-21 Avidence Therapeutics, Inc. Anti-osteoarthritis compounds and related compositions and methods

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH27357A (en) * 1989-09-22 1993-06-21 Fujisawa Pharmaceutical Co Pyrazole derivatives and pharmaceutical compositions comprising the same
MX9300141A (es) * 1992-01-13 1994-07-29 Smithkline Beecham Corp Compuestos de imidazol novedosos, procedimiento para su preparacion y composiciones farmaceuticas que lo contienen.
GB2306108A (en) * 1995-10-13 1997-04-30 Merck & Co Inc Treatment of Raf-mediated cancers with imidazole derivatives
ES2155817T3 (es) * 1997-12-22 2007-06-16 Bayer Pharmaceuticals Corp. Inhibicion de la actividad de la quinasa p38 utilizando ureas heterociclicas sustituidas con arilo y heteroarilo.
JP4316893B2 (ja) * 2001-05-16 2009-08-19 バーテックス ファーマシューティカルズ インコーポレイテッド Ｓｒｃおよび他のプロテインキナーゼのインヒビター
US6852727B2 (en) * 2001-08-01 2005-02-08 Merck & Co., Inc. Benzimisazo[4,5-f]isoquinolinone derivatives
US7582631B2 (en) * 2004-01-14 2009-09-01 Amgen Inc. Substituted heterocyclic compounds and methods of use
JP2008524329A (ja) * 2004-12-21 2008-07-10 メルク エンド カムパニー インコーポレーテッド 有糸***キネシン阻害剤
ES2552338T3 (es) * 2005-01-21 2015-11-27 Astex Therapeutics Limited Compuestos farmacéuticos
US20080021217A1 (en) * 2006-07-20 2008-01-24 Allen Borchardt Heterocyclic inhibitors of rho kinase
UY30892A1 (es) * 2007-02-07 2008-09-02 Smithkline Beckman Corp Inhibidores de la actividad akt
JP2010522770A (ja) * 2007-03-29 2010-07-08 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー Ａｋｔ活性の阻害物質
GB0709031D0 (en) * 2007-05-10 2007-06-20 Sareum Ltd Pharmaceutical compounds
TW200911798A (en) * 2007-08-02 2009-03-16 Amgen Inc PI3 kinase modulators and methods of use
JP5384611B2 (ja) * 2008-03-21 2014-01-08 ノバルティス アーゲー 新規ヘテロ環式化合物およびそれらの使用
NZ589844A (en) * 2008-06-19 2012-11-30 Millennium Pharm Inc Thiophene or thiazole derivatives and their use as phosphatidylinositol 3-kinase (PI3K) inhibitors
MX2010014572A (es) * 2008-06-27 2011-03-24 Novartis Ag Compuestos organicos.
CA2750935A1 (en) * 2009-01-30 2010-08-12 Millennium Pharmaceuticals, Inc. Heteroaryls and their use as pi3k inhibitors
WO2010127152A2 (en) * 2009-04-29 2010-11-04 Irm Llc Compounds and compositions as microsomal prostaglandin e synthase-1 inhibitors
MX2011012037A (es) * 2009-05-13 2012-02-28 Amgen Inc Compuestos de heteroarilo como inhibidores de pikk.
JO3002B1 (ar) * 2009-08-28 2016-09-05 Irm Llc مركبات و تركيبات كمثبطات كيناز بروتين
EP2627650A2 (en) * 2010-05-26 2013-08-21 Merck Sharp & Dohme Corp. N-phenyl imidazole carboxamide inhibitors of 3-phosphoinositide-dependent protein kinase-1
WO2012084678A1 (en) * 2010-12-23 2012-06-28 Syngenta Participations Ag Novel imidazoles useful as plant fungicides
US9090628B2 (en) * 2011-03-21 2015-07-28 Genentech, Inc. Benzoxazepin compounds selective for PI3K P110 delta and methods of use
KR102011534B1 (ko) * 2011-12-21 2019-08-16 오노 야꾸힝 고교 가부시키가이샤 인자 ＸＩａ 억제제로서 피리디논 및 피리미디논 유도체

Also Published As

Publication number Publication date
EP2793880A4 (en) 2015-06-24
US20130165483A1 (en) 2013-06-27
UY34539A (es) 2013-06-28
EP2793879A4 (en) 2015-07-01
EP2793880A1 (en) 2014-10-29
WO2013096642A1 (en) 2013-06-27
EP2793894A1 (en) 2014-10-29
UY34540A (es) 2013-06-28
WO2013096637A1 (en) 2013-06-27
AR089446A1 (es) 2014-08-27
TW201332989A (zh) 2013-08-16
UY34538A (es) 2013-06-28
JP2015506347A (ja) 2015-03-02
WO2013096630A1 (en) 2013-06-27
US20130165472A1 (en) 2013-06-27
JP2015503505A (ja) 2015-02-02
TW201332988A (zh) 2013-08-16
TW201331194A (zh) 2013-08-01
JP2015503504A (ja) 2015-02-02
EP2793894A4 (en) 2015-07-08
AR089447A1 (es) 2014-08-27
US20130165464A1 (en) 2013-06-27
EP2793879A1 (en) 2014-10-29

Similar Documents

Publication Publication Date Title
AR089445A1 (es) Heteroarilos y sus usos
AR094263A1 (es) Compuestos moduladores selectivos de proteinquinasas
HRP20180014T1 (hr) Hidrazid koji sadrži modulatore nuklearnog transporta i njihove uporabe
AR089189A1 (es) Inhibidores de quinasa
AR092306A1 (es) Antibacterianos de fenicol
AR106595A1 (es) COMPUESTOS HETEROCÍCLICOS COMO INHIBIDORES DE PI3K-g
AR082666A1 (es) Heteroarilos y sus usos
AR096242A1 (es) Inhibidores de acc y usos de los mismos
AR102177A1 (es) Compuestos de heteroarilo como inhibidores de btk y usos de los mismos
AR098136A1 (es) Compuestos de heteroarilo como inhibidores de btk y usos de los mismos
AR101265A1 (es) Ácidos carboxílicos heterocíclicos como activadores de guanilato ciclasa soluble
AR088020A1 (es) Compuestos heterociclicos como estimuladores de sgc
AR095609A1 (es) Compuestos de pirrolopiridina
JP2016522172A5 (es)
AR062270A1 (es) Compuestos de heteroarilo inhibidores de enzimas de activacion e1, composiciones farmaceuticas que los contienen y usos en desordenes asociados a proliferacion celular,tales como canceres y trastornos inflamatorios.
AR043859A1 (es) Inhibidores de serina proteasas, particularmente de la proteasa ns3-ns4a del hcv
AR084430A1 (es) Di/tri-aza-espiro-alcanos c
AR085316A1 (es) Derivados de pirrolo[2,3-b]piridina, utiles para la modulacion de quinasas
AR083450A1 (es) Heteroarilos y sus usos en el tratamiento de enfermedades proliferativas, inflamatorias o cardiovasculares
AR103598A1 (es) Ácidos bicíclicos[4,6,0]hidroxámicos como inhibidores de hdac
AR092703A1 (es) Peptidos ciclicos y su uso como medicinas
AR094123A1 (es) Compuesto triciclicos
AR098436A1 (es) Compuestos tricíclicos de piperidina
AR088378A1 (es) DERIVADOS DE N-CICLOPROPIL-N-(4,5,6,7-TETRAHIDRO-1H-INDAZOL-5-IL)-BENZAMIDA COMO INHIBIDOR DE LA 11b-HSD1
AR104934A1 (es) Moduladores de receptores nucleares

Legal Events

Date Code Title Description
FB Suspension of granting procedure